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a b s t r a c t
The atherogenic 7-oxysterols, 7-ketocholesterol (7-KC) and 7b-hydroxycholesterol (7bOHC), can directly
impair arterial function. Inter-conversion of 7-KC and 7bOHC has recently been shown as a novel role for
the glucocorticoid-metabolizing enzyme 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1). Since
this enzyme is expressed in vascular smooth muscle cells, we addressed the hypothesis that inter-
conversion of 7-KC and 7bOHC by 11b-HSD1 may contribute to regulation of arterial function.
Incubation (4e24 h) of aortic rings with either 7-KC (25 mM) or 7bOHC (20 mM) had no effect on
endothelium-dependent (acetylcholine) or -independent (sodium nitroprusside) relaxation. In contrast,
exposure to 7-KC (but not to 7bOHC) attenuated noradrenaline-induced contraction (Emax) after 4 h
(0.78  0.28 vs 0.40  0.08 mN/mm; p < 0.05) and 24 h (2.28  0.34 vs 1.56  0.48 mN/mm; p < 0.05).
Both 7-oxysterols were detected by GCMS in the aortic wall of chow-fed C57Bl6/J mice, with concen-
trations of 7-KC (1.41  0.81 ng/mg) higher (p ¼ 0.05) than 7bOHC (0.16  0.06 ng/mg). In isolated mouse
aortic rings 11b-HSD1 was shown to act as an oxo-reductase, inter-converting 7-KC and 7bOHC. This
activity was lost in aorta from 11b-HSD1/ mice, which had low oxysterol levels. Renal homogenates
from 11b-HSD1/mice were used to conﬁrm that the type 2 isozyme of 11b-HSD does not inter-convert
7-KC and 7bOHC.
These results demonstrate that 7-KC has greater effects than 7bOHC on vascular function, and that 11b-
HSD1 can inter-convert 7-KC and 7bOHC in the arterial wall, contributing to the regulation of 7-oxysterol
levels and potentially inﬂuencing vascular function. This mechanism may be important in the car-
dioprotective effects of 11b-HSD1 inhibitors.
 2012 Elsevier Masson SAS. All rights reserved.
1. Introduction
Pro-atherogenic 7-oxysterols form a large component (40%) of
oxidized LDL (oxLDL), of which 7-ketocholesterol (7-KC) contrib-
utes w30% [1]. 7-KC is toxic to cells in the vessel wall, and can
impair arterial function ex vivo [2]. Indeed, 7-KC and its metabolite
7b-hydroxycholesterol (7bOHC) inhibited endothelium-dependent,
acetylcholine-induced relaxation of rabbit aortic rings in vitro [2]. In
human umbilical vein endothelial cells (HUVECs), 7bOHC and 7-KC
reduced the histamine-activated release of nitric oxide [3]. This
inhibition of endothelial function by 7-oxysterols appears to be
independent of their cytotoxic effects [4], but its mechanism is
unclear. Importantly, 7-KC and 7bOHC differ in their pro-
atherogenic potential, with 7-KC implicated as the major pro-
inﬂammatory and cytotoxic oxysterol [5]. However, any differ-
ences between the functional effects of 7-KC and 7bOHC in the
vasculature have not been addressed.
The balance between 7-KC and 7bOHC in tissues may be actively
modulated. Recently, a novel route of metabolism of 7-oxysterols
has been described, involving the enzyme 11b-hydroxysteroid
dehydrogenase (11b-HSD) type 1. The primary role of 11b-HSD1 is
to catalyse the pre-receptor generation of glucocorticoids, allowing
tissue-speciﬁc ampliﬁcation of glucocorticoid receptor activation
Abbreviations: BHT, butylated hydroxytoluene; DMEM, Dulbecco’s modiﬁed
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[6]. Inactivation of glucocorticoids is catalysed by the type 2
isozyme of 11b-HSD (11b-HSD2) [7]. It is becoming increasingly
apparent that 7-oxysterols are alternative substrates for 11b-HSD1
[8,9], and inhibition of the enzyme can result in accumulation of 7-
KC [10]. Since both isozymes of 11b-HSD are present in the arterial
wall [11e14], where they are able to inter-convert glucocorticoids
[15], it is conceivable that inter-conversion of 7-oxysterols by these
enzymes has a role in modulating vascular function.
We used mice with targeted disruption of the 11b-HSD1 gene
(Hsd11b1) to investigate the hypothesis that 11b-HSD1 metabolises
7-oxysterols in the arterial wall, thus inﬂuencing 7-KC- and 7bOHC-
mediated modulation of arterial function.
2. Methods
2.1. Chemicals and stock solutions
All solvents were HPLC grade (Fisher, Hemel Hempstead, UK)
andwere prepared containing an anti-oxidant (0.01%w/v butylated
hydroxytoluene (BHT)) to prevent oxidative degradation of the
lipids [3]. Steroids and oxysterols were from Steraloids (Newport,
Rhode Island, USA), derivatization reagents from Fluka (Buchs,
Switzerland), tissue culture reagents from Lonza (Reading, UK) and
other chemicals from Sigma-Aldrich (Poole, Dorset, UK). Deute-
rium-labelled internal standards for GCMS were obtained from
CDN Isotopes (Qmx Laboratories, Essex, UK). Stock solutions
(30 mg/ml in ethanol with 250 mg/ml BHT) of 7-KC, 7bOHC and
7aOHC (an optical isomer of 7bOHC) were freshly prepared as
required. All steroids were prepared in 100% ethanol. Working
solutions for tissue culture were prepared in standard Dulbecco’s
modiﬁed Eagle’smedium (DMEM).Working solutions (25 mM7-KC;
20 mM 7bOHC) for myography were prepared by diluting the
appropriate stock solution in DMEM without L-Arginine (Arg) or
phenol red, but containing 1% charcoal-stripped foetal calf serum.
Thesewere themaximum concentrations of 7-oxysterols that could
be achieved without sample precipitation. The ﬁnal concentration
of vehicle (ethanol with 250 mg/ml BHT) was <0.2%.
2.2. Animals
Male mice (age 8e16 weeks) homozygous for disrupted alleles
of 11b-HSD1 (Hsd11b1/) [16] or 11b-HSD2 (Hsd11b2/) [7], on
a C57Bl6/J background [12] were bred in-house. Controls were age-
and sex-matched C57Bl6/J mice bred in-house [7,16]. Mice were
maintained on standard chow diet and tap water ad libitum, under
a 16 h/8 h light/dark cycle at 21e24 C. All procedures were per-
formed under UK Home Ofﬁce guidelines of humane care and
[17,18] animals were culled by cervical dislocation at 10.00 h.
Plasma (1ml) was collected from 2e3mice in EDTA-coated (1.6mg/
ml) vials (Sarstedt, Monovette) and separated by centrifugation
(2000 g, 4 C, 15 min), and an aliquot of BHT was added (50 mg/
5 ml). Tissues were snap-frozen and stored at 80 C until use.
Aortae for functional investigationwere removed frommice, placed
in PBS (37 C), cleaned of peri-adventitial fat and used for myog-
raphy. Aortae for oxysterol analysis were processed as described
below.
2.3. Functional effects of 7-oxysterols on isolated mouse aortic rings
Thoracic aortae were isolated from male C57Bl6/J mice (age 8e
10 weeks, n ¼ 12) and cut into four rings (2 mm in length). These
were either used immediately for short-term (4 h), or incubated in
a 24 well plate for extended (24 h), exposure to 7-oxysterols. For
short-term exposures, aortic rings were mounted on intra-luminal
wires in a small vessel wire myograph [19,20] containing DMEM
without L-Arg (37 C, continuously perfused with 95%O2: 5% CO2)
[14]. After the vessels had been equilibrated at their optimum
resting force they were contracted with KCl (125 mM, 3 times) to
conﬁrm viability and then incubated in the presence of: (1) 7-KC
(25 mM in DMEM without L-Arg), (2) 7bOHC (20 mM in DMEM
without L-Arg) or (3) vehicle alone (ethanol, with 50 mg/ml BHT in
DMEM without L-Arg), for 4 h (2 rings/treatment/mouse). The
incubating medium was replaced every 60 min. After 4 h cumula-
tive concentrationeresponse curves were obtained for 5-
hydroxytryptamine (5-HT; 1  109e1  104 M) and noradrena-
line (NA; 1  109e1  104 M). In addition, cumulative
concentrationeresponse curves were obtained for the vasodilators,
acetylcholine (ACh; 1109e1104 M, endothelium-dependent)
and sodium nitroprusside (SNP; 1  109e1  104 M,
endothelium-independent), following contraction with a sub-
maximal concentration of 5-HT (3  107e1  106 M). Contrac-
tile responses are expressed as force per unit length (mN/mm).
Relaxations were expressed as a percentage of the contraction in
response to the EC80 of 5-HT (% 5-HT).
For extended exposures [14], aortic rings were placed in a 24
well plate and immersed in 1 ml DMEM (without L-Arg) containing
either 7-KC (25 mM), 7bOHC (20 mM), or vehicle (ethanol with
50 mg/ml BHT) and incubated overnight in a humidiﬁed incubator
(37 C; 5% CO2). These vessels were then mounted in a myograph
and functional studies performed, as described above, in the
continued presence of the appropriate 7-oxysterol or vehicle.
2.4. Determination of plasma and aortic levels of 7-oxysterols and
cholesterol
Concentrations of cholesterol and 7-oxysterols in the plasma
and aortae were quantiﬁed by GCMS. Aortae from Hsd11b1/ or
C57Bl6/J mice were pooled from two animals, washed in PBS con-
taining EDTA (0.5 mM), crushed under liquid nitrogen and
homogenized. Protein concentration was determined using Brad-
ford assay (Biorad, UK). Deuterium-labelled ([2H], d7) internal
standards (IS) were added (50 ml) and lipids were extracted into
chloroform/methanol (2:1, 8 ml) [21,22]. Samples were puriﬁed
using Bond Elute Diol columns (100 mg, 1 ml; Varian, UK) [23] and
hydrolysed following mild saponiﬁcation [24,25]. Oxidized lipids
and cholesterol were extracted from neutralized samples (0.35 ml,
20% acetic acid) into diethyl ether (4 ml, 0.01% BHT) and evaporated
to dryness under argon. Total cholesterol and 7-oxysterol concen-
trations were measured by GCMS and corrected for aortic protein
levels.
2.5. Metabolism of 7-oxysterols by 11b-HSD1 and 11b-HSD2
in vitro
2.5.1. In the mouse aorta
Rings (2 mm long) of aortae from C57Bl/J6 and Hsd11b1/mice
(n ¼ 8/group) were placed in a 24 well plate (1/well, in duplicate)
and immersed in 1 ml DMEM (without L-Arg) containing 7-KC
(25 mM), 7bOHC (20 mM), 7aOHC (20 mM) or vehicle (ethanol,
with 50 mg/ml BHT). Samples were incubated overnight in
a humidiﬁed incubator (37 C; 5% CO2) then blotted dry on tissue
paper and weighed to allow calculation of conversion velocity
(pmol/mg/day). Medium was removed and deuterium-labelled
internal standards (IS; [2H], d7-7-KC (40 ng), [2H], d7-7bOHC
(10 ng) and [2H], d7-cholesterol (10 mg)) added in a single aliquot
(50 ml). [2H], d7-7bOHC was used as an internal standard for
quantitation of both 7aOHC and 7bOHC. Argon gas was ﬂushed
through all samples and oxysterols were extracted (8 ml, 100 g,
15 min) from media with a mixture of hexane:2-propanol (60:40)
[26]. The organic phases were combined, evaporated under
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a stream of argon and residues dissolved in chloroform:methanol
(2:1, 350 ml) before storing at 20 C for analysis by GCMS. Results
were subsequently corrected for aortic ring weight. In all assays
appropriate positive controls were included, with aortic rings
incubated with [3H], d4-corticosterone or [3H], d4-11-
dehydrocorticosterone (30 nM) to verify the activity of 11b-HSD
isozymes. Samples were processed for analysis as before [27].
2.5.2. In kidney
Murine kidneys contain both isoforms of 11b-HSD.Homogenates
of kidneys fromHsd11b1/mice (which lack 11b-HSD1) were used
as a source ofmurine 11b-HSD2,with kidneys fromC57Bl6/J mice as
controls. Kidneyswerehomogenized inphosphate buffer as detailed
[10]. Homogenates (400 mg/ml) were incubated with 7-oxysterols
(20 mM) and the appropriate cofactor (2 mM): NADþ or NADPþ for
dehydrogenase reactions; NADH or NADPH for reductase reactions.
In all assays conversion of dexamethasone (Dex) and 11-
dehydrodexamethasone (11-DHDex; 40 mM) was used as a positive
control for conﬁrmation of 11b-HSD isozyme activity [28].
2.6. Chromatographic analyses
2.6.1. Analysis of 7-oxysterols by gas chromatography/mass
spectrometry (GCMS)
7-Oxysterols and cholesterol were converted to trimethylsilyl
ether derivatives using a pyridine:hexamethyldisilazan:trimethyl-
chlorosilane mixture (350 ml, 3:2:1, v/v/v) [29,30]. The derivatized
cholesterolmetabolites were dissolved in 2%N,O-Bis(trimethylsilyl)
triﬂuoroacetamide (BSTFA) in decane (80 ml) and eluted as follows:
initial temperature 180 C (1 min), increased by 35 C/min until
270 C was achieved (1 min) and then increased by 4 C/min to
300 C (12 min). The ovenwas then cooled by10 C/min to 250 C
(1 min). The injection temperature was 270 C.
A capillary gas chromatograph (Trace GC, Thermo) was coupled
to an ion-trap, Polaris Q (Thermo, Hemel Hempstead, UK) mass
spectrometer (MS) and equipped with a BPX5 capillary column
(25 m, 0.32 mm internal diameter and 0.25 mm ﬁlm thickness; SGE,
Alva, UK) and operated in SIM mode with electron impact (70 eV),
ion source, transfer line and interface temperatures of 200 C, 220 C
and 250 C respectively. Derivatives of 7-oxysterols and cholesterol
were quantiﬁed by monitoring the following ions (m/z): 7-KC (472,
16.5 min), 7a/bOH (456, 12.3 & 14.1 min), d7-7-KC (479, 16.35 min),
d7-7bOHC (463, 13.8 min) and d7-cholesterol (375, 12.9 min). Limits
of detection were assigned as 3:1 signal to noise ratio. Compounds
were quantiﬁed by the ratio of area under peak of interest to area
under peak of internal standard against a standard curve.
2.6.2. Quantitation of steroids by high pressure liquid
chromatography
Radio-labelled glucocorticoids were separated by reverse phase
HPLC (Symmetry C8 column maintained at 35 C; column length,
15 cm, internal diameter 4.6mm, pore size 5 mm,Waters, Edinburgh,
UK) and quantiﬁed by on-line liquid scintillation counting (2 ml/
min; GoldFlow, Meridian, Surrey, UK). Total run time was 35 min
(elution times of epi-cortisol, 11-dehydrocorticosterone and corti-
costerone were typically 12 min, 21 min and 31 min, respectively,
with mobile phase of water:acetonitrile:methanol (60:15:25) at
1 ml/min). Dex and 11-DHDexwere separated using a mobile phase
of water:acetonitrile:methanol (55:20:25) at 1 ml/min with typical
retention times forepi-cortisol (10min),11-DHDex (12min) andDex
(16 min). UV detection of all steroids was achieved at 240 nm and
epi-cortisol was used as an internal standard. Steroids were quan-
tiﬁed by the ratio of area under peak of interest to area under peak of
internal standard against a standard curve.
2.7. Statistical analysis
All data are mean  standard error of the mean (SEM) where n
indicates the number of different animals. Values were compared
using unpaired Student’s t-tests or 1-way ANOVA with Dunnett’s
multiple comparison post-tests, as appropriate. All analyses were
performed using Graph Pad Prism v5.0 (GraphPad Software Inc. San
Diego, USA). Statistical signiﬁcance was assumed when p < 0.05.
3. Results
3.1. 7-KC, but not 7bOHC, alters vascular function in vitro
Short-term exposure (4 h) of aortae from C57Bl6/J mice to 7-KC
(25 mM), but not 7bOHC (20 mM), produced a small reduction
(p¼ 0.049) in NA-inducedmaximum contraction (Emax), but had no
effect on the sensitivity (pD2) of this response (Fig. 1A, B; Table 1A).
5-HT-mediated contraction was unaltered by exposure to either
oxysterol (Table 1A). Pre-treatment of vessels with either 7-KC or
7bOHC did not alter endothelium-dependent relaxation to ACh
(Fig. 1C, D). An apparent increase in maximal response to
endothelium-independent, SNP-mediated vasorelaxation after
incubation with either 7-KC (p ¼ 0.05) or 7bOHC (p ¼ 0.08) was of
borderline statistical signiﬁcance (Fig. 1E, F).
Long-term (24 h; Fig. 2) exposure of aortae from C57Bl6/J mice
to 7-KC (25 mM), but not 7bOHC (20 mM), produced a reduced
maximum contraction (Emax, p ¼ 0.049), but no change in sensi-
tivity (pD2) to NA (Fig. 2A, B; Table 1 B). Prolonged incubation with
either 7-oxysterol had no effect on 5-HT-mediated contraction or
endothelium-dependent (Fig. 2C, D) or -independent (Fig. 2E, F)
relaxation (Table 1 B).
3.2. 7-Oxysterols are present in the mouse aortic wall and altered
by deletion of 11b-HSD1
7-KC (3.52  2.85 nmol/g tissue) and 7bOHC (0.40  0.15 nmol/
g) were both detected in themouse thoracic aortae with levels of 7-
KC signiﬁcantly higher than 7bOHC (p ¼ 0.05; n ¼ 12). In aortae
from Hsd11b1/ mice, 7-KC was only present in levels above the
limit of detection in 3 (of 8) samples and 7bOHC was also low
(0.12  0.02 nmol/mg). Plasma levels of 7-oxysterols were not
different in Hsd11b1/ mice compared with C57Bl/6J mice (7-KC;
0.133  0.016 versus 0.091  0.022 mM; 7bOHC 0.024  0.002
versus 0.023  0.005 mM, respectively) although total plasma
cholesterol was lower (0.45  0.14 versus 1.03  0.19 mM, p < 0.05).
3.3. 7-Oxysterols are metabolized by 11b-HSD1 but not by
11b-HSD2
As expected [15], glucocorticoids were inter-converted by
incubationwith intact mouse aortic rings. The velocity of reduction
of 11-dehydrocorticosterone to corticosterone (Fig. 3A) proceeded
considerably (w10) faster than the dehydrogenation of cortico-
sterone to 11-dehydrocorticosterone. Reduction of 11-
dehydrocorticosterone was attenuated in mice lacking 11b-HSD1,
whereas deletion of this enzyme produced only a small (though
signiﬁcant) increase in the dehydrogenation of corticosterone (to
11-dehydrocorticosterone) (Fig. 3A). The oxysterols 7-KC and
7bOHC were also inter-converted by incubation with intact mouse
aortic rings. In contrast to glucocorticoids, however, the velocities
of reduction of 7-KC (to 7bOHC) and of dehydrogenation of 7bOHC
(to 7-KC) were similar following incubationwithmouse aortic rings
(Fig. 3B). Genetic disruption of Hsd11b1 signiﬁcantly reduced the
velocity of conversion of both 7-KC and 7bOHC (Fig. 3B), with
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96  6% of added substrates being recovered. 7-KC was not inter-
converted with 7aOHC in aortic rings (data not shown).
Hsd11b1/ mouse kidney homogenates (a rich source of 11b-
HSD2; [31]) were used to determine whether 7-oxysterols are
metabolised by this isozyme. As with the aortic rings, conversion of
glucocorticoids was used as a positive control for activity of 11b-
HSD2 [14,27]. As anticipated, glucocorticoids were metabolized by
mouse renal homogenates with preferential generation of 11-
DHDex from Dex (oxidation; not shown). In contrast, renal
homogenates did not inter-convert any of the 7-oxysterols (7aOHC,
7bOHC or 7-KC). Unrecovered substrate wasw3% or lower for each
compound (7aOHC, 1.9  0.7%; 7bOHC, 3.2  0.3%; KC, 2.1  0.3%).
4. Discussion
This study shows for the ﬁrst time that 11b-HSD1, but not 11b-
HSD2, catalyses the conversion of 7-oxysterols in the vascular wall.
Previous work has shown that murine and human 11b-HSD1
Fig. 1. Short-term (4 h) exposure to 7-ketocholesterol induces agonist-speciﬁc functional changes in isolated mouse aorta. Endothelium-intact aortic rings from C57Bl6/J mice were
incubated (4 h) with 7-ketocholesterol (7-KC, 25 mM open squares) or 7b-hydroxycholesterol (7bOHC, 20 mM, open squares) and compared with vehicle (ethanol containing 50 mg/
ml butylated hydroxytoluene)-treated control (ﬁlled squares). Incubation with 7-KC (A), but not 7bOHC (B), produced a small reduction of noradrenaline (NA)-mediated contraction
(p ¼ 0.04). Incubations had no effect on acetylcholine (ACh)-mediated relaxation (C, D) whereas 7-KC (E) (but not 7bOHC (F)), produced a trend towards increased sodium
nitroprusside (SNP)-mediated relaxation (p ¼ 0.054). Relaxations were expressed on a scale where the response to 5-HT represented 100% and return to baseline was expressed as
0%. All points represent mean  SEM, compared by 1-way ANOVA with Tukey’s post hoc test, n ¼ 6e8.
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converts 7-KC to 7bOHC in the liver and in cultured adipocytes
[8,9]. We provide evidence that murine 11b-HSD1 reduces 7-KC to
7bOHC in the vessel wall but, furthermore, that it also oxidizes
7bOHC to 7-KC. Use of Hsd11b1/ mice conﬁrmed that 11b-HSD1
was the sole enzyme responsible for metabolism of 7-KC and
7bOHC in the aortic wall and that deletion of 11b-HSD1 alters
vascular 7-oxysterol concentrations. Functional investigations
showed differential effects of 7-KC and 7bOHC on vascular function,
suggesting that this 11b-HSD1-mediated inter-conversion of 7-
oxysterols may inﬂuence 7-KC-mediated inhibition of arterial
contraction.
7-KC and 7bOHC have both been shown previously to inhibit
endothelium-dependent vasorelaxation [32], cause endothelial cell
death, and induce production of radical oxygen species [17,33]. This
is consistent with the ability of oxidized lipids to impair the
endothelium-dependent relaxation of aortic segments from
hyperlipidaemic mice [34]. The lack of impact of exposure to oxy-
sterols on endothelium-dependent relaxation was surprising given
the previous indications that both 7-KC and 7bOHC inhibit endo-
thelial function [2,3,32] ex vivo. One possible explanation for lack of
effect on vasorelaxation is the use of a low concentration of 7-
oxysterol (20e25 mM) compared with previous studies (180e
270 mM; [2,3,32]). The concentrations used for our investigations
were the highest we could achieve without precipitation and are
consistent with that used (25 mM) to show 7-oxysterol-mediated
smooth muscle apoptosis in vitro [35]. Furthermore, a recent
investigation using high concentrations of 7-KC (205 mM) found no
effect of ex vivo incubation on ACh-mediated relaxation of mouse
aorta [36].
Intriguingly at the concentrations used in this investigation,
there was an inhibition of smooth muscle cell contraction by 7-KC
that was not observed with 7bOHC. The mechanism involved is
unclear but the effect was selective for noradrenaline, suggesting
an impairment in the a1-adrenoceptor signalling pathway.
Impaired contractility is consistent with 7-KC at this concentration
having detrimental effects on vascular smooth muscle cells [35].
These results suggest, therefore, that the balance of 7-KC and
7bOHC may have functional and structural implications in the
arterial wall.
The concentrations of 7-oxysterols in the vessels of C57Bl6/J
mice are consistent with those reported previously in human
plasma and vessels [1,24]. Since circulating 7-oxysterols can be
sequestered by cells in the vessel wall [37], we assessed the
potential of vascular 11b-HSD1 to inter-convert 7-oxysterols in this
tissue. Plasma 7-oxysterol levels were not altered in Hsd11b1/
mice although total plasma cholesterol was substantially lower.
Consistent with previous reports of reduced intra-vascular
cholesterol accumulation with inhibition of 11b-HSD1 [38], we
found lower levels of all 7-oxysterols in the aortae of Hsd11b1/
mice. It was, therefore, difﬁcult to assess intra-vascular 7-
KC:7bOHC ratios, since 7-KC levels in particular were near to the
detection limit, but the data suggest that 7-KC levels are dispro-
portionately reduced in Hsd11b1/ mice, consistent with the
enzyme acting predominantly as an oxidase (converting 7bOHC to
7-KC) in vivo.
The ex vivo incubation of aortic rings described here has not
previously been used to assess inter-conversion of 7-oxysterols.
This approach conﬁrmed that the stability of 7-oxysterols can be
preserved during incubation, as both 7-KC and 7bOHC were
successfully recovered from DMEM. It had been postulated that 7-
oxysterolsmay be taken up by the vessels during incubation but the
percentage recovery of 7-oxysterols from reaction mixtures did not
support this. Preparation of concentrated stock solutions of the 7-
oxyserols proved unexpectedly difﬁcult, despite using published
methodology [3], with oxysterols precipitating at high concentra-
tions. Based on our own experiences and advice from other groups
7-oxysterol solutions were prepared in DMEM containing FCS
containing an antioxidant (BHT; to prevent oxidative degradation
of the lipids [3]). It is unlikely that BHT would have a detrimental
effect on vascular function as it did not alter histamine-induced NO
production in cultured HUVECs [32].
Ex vivo assays clearly demonstrated that incubation of 7-
oxysterols with mouse aortic rings results in the conversion of
7bOHC to 7-KC and 7-KC to 7bOHC, but not inter-conversion of
7aOHC and 7-KC. This is consistent with results generated in rats
[9,10] and humans [39] but contrasts with the demonstration that
11b-HSD1 in hamsters can inter-convert 7aOHC and 7-KC [40]. The
ability of 11b-HSD1 to inter-convert 7-oxysterols explains why
carbenoxolone, a non-selective 11b-HSD inhibitor, attenuates
7-oxysterol metabolism in rat hepatic microsomes [10]. Interest-
ingly, in contrast to the predominant reductase direction
(11-dehydrocorticosterone to corticosterone) shown for metabo-
lism of glucocorticoids, murine vascular 11b-HSD1 showed similar
activity as both reductase (7bOHC to 7-KC) and dehydrogenase
(7-KC to 7bOHC) for inter-conversion of oxysterols, consistent with
previous reports in liver [9,39]. Under these assay conditions, the
reaction velocity for inter-conversion of oxysterols was consider-
ably (approximately 10-fold) higher than for reduction of 11-
dehydrocorticosterone. This contrasts with the demonstration of
similar reaction velocities observed in other studies [9,40] and is
likely to be a consequence of study design as substrate concentra-
tions were higher (w800) for the oxysterols than for the
glucocorticoids.
Residual metabolism of glucocorticoids in aortae from
Hsd11b1/ mice is consistent with vascular 11b-HSD2 expression
[14,20]. Virtually no residual inter-conversion of 7bOHC and 7-KC
Table 1
Exposure to 7-oxysterols caused an agonist-selective inhibition of contraction, but
had no effect on relaxation, of mouse aortic rings in vitro.
A) Short (4 h) incubation
(i) 7-Ketocholesterol (7-KC)
Agonist Emax (mN/mm or % relaxation) pD2/logIC50
Vehicle 7-KC Vehicle 7-KC
NA 0.79  0.28 0.40  0.08* 6.70  0.34 7.92  0.48
5-HT 3.01  0.37 2.47  0.26 6.36  0.08 6.55  0.06
ACh 46.3  5.3 47.1  7.0 6.32  0.09 6.48  0.09
SNP 104.8  3.8 122.0  8.3 7.53  0.22 7.56  0.12
(ii) 7b-Hydroxycholesterol (7bOHC)
Agonist Emax (mN/mm or % relaxation) pD2/logIC50
Vehicle 7bOHC Vehicle 7bOHC
NA 1.60  0.36 1.80  0.61 6.90  0.17 6.80  0.22
5-HT 2.80  0.28 3.30  0.32 6.40  0.04 6.50  0.05
ACh 47.7  6.2 59.1  4.8 7.30  0.32 7.10  0.16
SNP 116.7  10.3 121.7  12.0 7.90  0.11 8.20  0.11
B) Extended (24 h) Incubation
(i) 7-Ketocholesterol (7-KC)
Agonist Emax(mN/mm or % relaxation) pD2/logIC50
Vehicle 7-KC Vehicle 7-KC
NA 2.28  0.34 1.56  0.48* 7.79  0.16 7.94  0.33
5-HT 4.03  0.24 3.63  0.33 6.61  0.05 6.60  0.12
ACh 66.9  4.5 75.4  6.4 7.47  0.13 7.35  0.21
SNP 108.6  5.0 106.0  1.5 7.04  0.17 6.95  0.19
(ii) 7b-Hydroxycholesterol (7bOHC)
Agonist Emax (mN/mm or % relaxation) pD2/logIC50
Vehicle 7bOHC Vehicle 7bOHC
NA 1.21  0.14 1.16  0.12 6.55  0.06 6.24  0.03
5-HT 2.43  0.14 2.88  0.15 6.51  0.15 6.90  0.32
ACh 46.4  5.6 60.3  5.2 7.17  0.15 6.97  0.31
SNP 104.6  3.46 109.5  1.94 6.84  0.16 6.72  0.19
All values represent mean  SEM, compared by unpaired Student’s t-test (vehicle vs
7-oxysterol), n ¼ 4e8, *p < 0.05. NA, noradrenaline; 5-HT, 5-hydroxytryptamine;
ACh, acetylcholine; SNP, sodium nitroprusside.
Bold represents signiﬁcant differences in the data.
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was observed in aortae from mice lacking 11b-HSD1. Lack of 7-
oxysterol metabolism by 11b-HSD2 was conﬁrmed using kidney
homogenates (since the kidney is rich in 11b-HSD2 [15]; using
kidneys from Hsd11b1/ mice ensured that there was no inter-
ference from this isozyme). This ﬁnding is consistent with the
previous attribution of 7-oxysterol metabolism solely to the action
of 11b-HSD1 in hamster [40], rat [9,10], guinea pig [9,41] and
human [39]. There was, however, a notable loss of substrate in the
reaction mixtures; suggesting incomplete recovery of substrate,
non-enzymatic degradation, or formation of alternative products
[42]. There was no loss of substrate in blank samples (containing
buffer but no tissue homogenate), conﬁrming chemical stability of
7-oxysterols during the incubation.
Direct action on the cells of the arterial wall may not present the
only mechanisms through which oxysterols can inﬂuence regula-
tion of arterial function and structure. Previous work in our group
[43] has indicated that the ability of oxysterols to act as substrates
for 11b-HSD1 also makes them potential competitive inhibitors of
glucocorticoid metabolism. This presents the possibility that
endogenous 7-oxysterols contribute to regulation of 11b-HSD1-
dependent glucocorticoid generation. Glucocorticoids can interact
directly with the arterial wall to enhance vasoconstriction [44],
impair endothelium-dependent relaxation [45], inhibit angiogen-
esis [27] and reduce vascular lesion formation. There is increasing
evidence that these interactions are regulated by the activity of
11b-HSD1 [27,38]. However, it is notable that no systematic
Fig. 2. Long-term (24 h) exposure to 7-ketocholesterol induces agonist selective functional changes in isolated mouse aorta. Endothelium-intact aortic rings from C57Bl6/J mice
were incubated (24 h) with 7-ketocholesterol (7-KC, 25 mM open squares) or 7b-hydroxycholesterol (7bOHC, 20 mM, open squares) and compared with vehicle (ethanol containing
50 mg/ml butylated hydroxytoluene)-treated control (ﬁlled squares). Incubation with 7-KC (A), but not 7bOHC (B), produced a small reduction of noradrenaline (NA)-mediated
contraction (p ¼ 0.05). Incubations had no effect on acetylcholine (ACh)-mediated (C, D) or sodium nitroprusside (SNP)-mediated (E, F) relaxation. All points represent mean  SEM,
compared by 1-way ANOVA with Tukey’s post hoc test, n ¼ 6e8.
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difference in vascular function has been observed in vessels from
Hsd11b1/ mice [20], so whether alterations in either 7-oxysterol
or glucocorticoids inﬂuences physiological vascular function
remains uncertain. Perhaps interactions of oxysterols with 11b-
HSD1 are more important in pathology. In healthy individuals, the
maximum concentrations of 7-oxysterols [46,47] are lower than
those in patients with atherosclerosis who may have levels of 7-
oxysterols in the micromolar range [1]. It is plausible that inhibi-
tion of 11b-HSD1-mediated glucocorticoid generation in conditions
of 7-oxysterol excess may have an indirect impact on arterial
function and remodelling.
Metabolism of 7-oxysterols by 11b-HSD1 may also have impli-
cations for the development of new therapies. Selective 11b-HSD1
inhibition prevents atherosclerosis [38] and is being developed for
treatment of cardiovascular risk factors [48], but the mechanisms
responsible for this atheroprotective effect have not been demon-
strated. It is conceivable that the beneﬁcial effects of 11b-HSD1
inhibition are a consequence of prevention of 7-oxysterol inter-
conversion as well as glucocorticoid metabolism.
5. Conclusions
11b-HSD1 inﬂuences 7-oxysterol concentrations within the
arterial wall. By altering the balance of 7-ketocholesterol and 7b-
hydroxycholesterol, 11b-HSD1 may modulate their speciﬁc effects
on vascular function, especially in disease states in which oxysterol
levels are increased.
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